A study led by Massachusetts General Hospital (MGH) investigators identifies two subanesthetic dosage levels of the anesthetic drug ketamine that appear to provide significant symptom relief to patients with treatment-resistant depression. See the report in Science Daily.

Lead Research/Investigator:

Maurizio Fava, MD, executive director of the Clinical Trials Network & Institute in the MGH Department of Psychiatry

 

Source: Science Daily

Pin It on Pinterest